362 related articles for article (PubMed ID: 34717627)
1. Impact of prediabetes and diabetes on 3-year outcome of patients treated with new-generation drug-eluting stents in two large-scale randomized clinical trials.
Ploumen EH; Pinxterhuis TH; Zocca P; Roguin A; Anthonio RL; Schotborgh CE; Benit E; Aminian A; Danse PW; Doggen CJM; von Birgelen C; Kok MM
Cardiovasc Diabetol; 2021 Oct; 20(1):217. PubMed ID: 34717627
[TBL] [Abstract][Full Text] [Related]
2. Three-year clinical outcome in all-comers with "silent" diabetes, prediabetes, or normoglycemia, treated with contemporary coronary drug-eluting stents: From the BIO-RESORT Silent Diabetes study.
Ploumen EH; Buiten RA; Kok MM; Doggen CJM; van Houwelingen KG; Stoel MG; de Man FHAF; Hartmann M; Zocca P; Linssen GCM; Doelman C; Kant GD; von Birgelen C
Catheter Cardiovasc Interv; 2020 Aug; 96(2):E110-E118. PubMed ID: 31625262
[TBL] [Abstract][Full Text] [Related]
3. "Silent" Diabetes and Clinical Outcome After Treatment With Contemporary Drug-Eluting Stents: The BIO-RESORT Silent Diabetes Study.
von Birgelen C; Kok MM; Sattar N; Zocca P; Doelman C; Kant GD; Löwik MM; van der Heijden LC; Sen H; van Houwelingen KG; Stoel MG; Louwerenburg JHW; Hartmann M; de Man FHAF; Linssen GCM; Doggen CJM; Tandjung K
JACC Cardiovasc Interv; 2018 Mar; 11(5):448-459. PubMed ID: 29454724
[TBL] [Abstract][Full Text] [Related]
4. Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents: 3-Year Outcomes of BIO-RESORT.
Buiten RA; Ploumen EH; Zocca P; Doggen CJM; Danse PW; Schotborgh CE; Scholte M; van Houwelingen KG; Stoel MG; Hartmann M; Tjon Joe Gin RM; Somi S; Linssen GCM; Kok MM; von Birgelen C
JACC Cardiovasc Interv; 2019 Sep; 12(17):1650-1660. PubMed ID: 31422087
[TBL] [Abstract][Full Text] [Related]
5. High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial.
Zocca P; Kok MM; van der Heijden LC; Danse PW; Schotborgh CE; Scholte M; Hartmann M; Linssen GCM; Doggen CJM; von Birgelen C
Cardiovasc Drugs Ther; 2018 Dec; 32(6):567-576. PubMed ID: 30143879
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
7. Outcomes Among Diabetic Patients Undergoing Percutaneous Coronary Intervention With Contemporary Drug-Eluting Stents: Analysis From the BIONICS Randomized Trial.
Konigstein M; Ben-Yehuda O; Smits PC; Love MP; Banai S; Perlman GY; Golomb M; Ozan MO; Liu M; Leon MB; Stone GW; Kandzari DE
JACC Cardiovasc Interv; 2018 Dec; 11(24):2467-2476. PubMed ID: 30573057
[TBL] [Abstract][Full Text] [Related]
8. Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents.
Baber U; Stefanini GG; Giustino G; Stone GW; Leon MB; Sartori S; Aquino M; Steg PG; Windecker S; Wijns W; Serruys PW; Valgimigli M; Morice MC; Camenzind E; Weisz G; Smits PC; Kandzari DE; von Birgelen C; Dangas GD; Galatius S; Jeger RV; Kimura T; Mikhail GW; Itchhaporia D; Mehta L; Ortega R; Kim HS; Kastrati A; Chieffo A; Mehran R
Circ Cardiovasc Interv; 2019 Jul; 12(7):e007734. PubMed ID: 31288561
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of contemporary drug-eluting stents in patients with and without diabetes mellitus: Multigroup propensity-score analysis using data from stent-specific, multicenter, prospective registries.
Kwon O; Lee JB; Ahn JM; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ;
Catheter Cardiovasc Interv; 2020 Aug; 96(2):243-252. PubMed ID: 31478593
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of fibrinogen in patients with coronary artery disease and prediabetes or diabetes following percutaneous coronary intervention: 5-year findings from a large cohort study.
Yuan D; Jiang P; Zhu P; Jia S; Zhang C; Liu Y; Liu R; Xu J; Tang X; Zhao X; Gao R; Yang Y; Xu B; Gao Z; Yuan J
Cardiovasc Diabetol; 2021 Jul; 20(1):143. PubMed ID: 34271936
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis.
Giustino G; Baber U; Aquino M; Sartori S; Stone GW; Leon MB; Genereux P; Dangas GD; Chandrasekhar J; Kimura T; Salianski O; Stefanini GG; Steg PG; Windecker S; Wijns W; Serruys PW; Valgimigli M; Morice MC; Camenzind E; Weisz G; Smits PC; Kandzari DE; Galatius S; Von Birgelen C; Saporito R; Jeger RV; Mikhail GW; Itchhaporia D; Mehta L; Ortega R; Kim HS; Kastrati A; Chieffo A; Mehran R
JACC Cardiovasc Interv; 2016 Apr; 9(7):674-84. PubMed ID: 27056305
[TBL] [Abstract][Full Text] [Related]
12. Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials.
Cassese S; Kufner S; Xhepa E; Byrne RA; Kreutzer J; Ibrahim T; Tiroch K; Valgimigli M; Tölg R; Fusaro M; Schunkert H; Laugwitz KL; Mehilli J; Kastrati A
Clin Res Cardiol; 2016 Jul; 105(7):575-84. PubMed ID: 26689707
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With Diabetes Mellitus: The RESERVOIR Clinical Trial.
Romaguera R; Gómez-Hospital JA; Gomez-Lara J; Brugaletta S; Pinar E; Jiménez-Quevedo P; Gracida M; Roura G; Ferreiro JL; Teruel L; Montanya E; Fernandez-Ortiz A; Alfonso F; Valgimigli M; Sabate M; Cequier A
JACC Cardiovasc Interv; 2016 Jan; 9(1):42-50. PubMed ID: 26762910
[TBL] [Abstract][Full Text] [Related]
14. Ten-Year Clinical Outcomes of Biodegradable Versus Durable Polymer New-Generation Drug-Eluting Stent in Patients With Coronary Artery Disease With and Without Diabetes Mellitus.
Lenz T; Koch T; Joner M; Xhepa E; Wiebe J; Coughlan JJ; Aytekin A; Ibrahim T; Fusaro M; Cassese S; Laugwitz KL; Schunkert H; Kastrati A; Kufner S;
J Am Heart Assoc; 2021 Jun; 10(12):e020165. PubMed ID: 34075784
[TBL] [Abstract][Full Text] [Related]
15. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
16. Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial.
Kufner S; Byrne RA; Mehilli J; Massberg S; Birkmeier KA; Schulz S; Pache J; Schömig A; Kastrati A
Catheter Cardiovasc Interv; 2013 Nov; 82(6):E769-76. PubMed ID: 23754254
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness and Safety of New-Generation Versus Early-Generation Drug-Eluting Stents According to Complexity of Coronary Artery Disease: A Patient-Level Pooled Analysis of 6,081 Patients.
Piccolo R; Pilgrim T; Heg D; Franzone A; Rat-Wirtzler J; Räber L; Silber S; Serruys PW; Jüni P; Windecker S
JACC Cardiovasc Interv; 2015 Nov; 8(13):1657-66. PubMed ID: 26585615
[TBL] [Abstract][Full Text] [Related]
18. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.
Sabaté M; Räber L; Heg D; Brugaletta S; Kelbaek H; Cequier A; Ostojic M; Iñiguez A; Tüller D; Serra A; Baumbach A; von Birgelen C; Hernandez-Antolin R; Roffi M; Mainar V; Valgimigli M; Serruys PW; Jüni P; Windecker S
JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419
[TBL] [Abstract][Full Text] [Related]
19. Ten-year Outcomes After Drug-Eluting Stents or Bypass Surgery for Left Main Coronary Disease in Patients With and Without Diabetes Mellitus: The PRECOMBAT Extended Follow-Up Study.
Jeong YJ; Ahn JM; Hyun J; Lee J; Kim JH; Yang Y; Choe K; Park H; Kang DY; Lee PH; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park SJ; Park DW
J Am Heart Assoc; 2021 Jul; 10(14):e019834. PubMed ID: 34238026
[TBL] [Abstract][Full Text] [Related]
20. Everolimus Eluting Stents in Patients with Diabetes Mellitus and Chronic Kidney Disease: Insights from the TUXEDO Trial.
Bangalore S; Abhaichand R; Mullasari A; Jain R; Chand RKP; Arambam P; Kaul U
Cardiovasc Revasc Med; 2019 Dec; 20(12):1075-1080. PubMed ID: 31036397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
